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Resumo
Introdução: Aspectos psicológicos, 
transtornos psiquiátricos e qualidade de vida 
são frequentemente avaliados em pacientes 
em terapia renal substitutiva. Entretanto, 
não existem estudos que analisem 
ansiedade, depressão e qualidade de vida 
especificamente em pacientes portadores 
de doenças renais familiares. Objetivo: 
Avaliar a frequência de traços e estados 
ansiosos e depressivos e qualidade de vida, 
verificando as possíveis relações com os 
principais achados laboratoriais, clínicos, 
socioeconômicos e culturais de pacientes 
portadores de glomerulonefrites (GN) 
familiares ou de doença renal policística 
autossômica dominante (DRPAD). 
Métodos: Noventa pacientes adultos (52 GN 
familiares e 38 DRPAD) foram avaliados 
utilizando Inventário de Ansiedade Traço-
Estado (IDATE), Inventário de Depressão 
Beck (Beck) e Questionário de Qualidade de 
Vida Short Form-36 (SF-36), além de uma 
breve entrevista. Resultados: Observou-se 
ansiedade moderada em ambos os grupos, 
depressão em 34,6% das GN e em 60,5% 
das DRPAD. De um modo geral, ansiedade 
e depressão associaram-se mais ao gênero 
feminino na GN familiar e ao pior nível 
educacional na DRPAD. Pacientes de ambos 
os grupos apresentaram duas dimensões 
mais afetadas no que se refere à qualidade 
de vida, o aspecto emocional e a percepção 
geral do estado de saúde. Além disso, o 
SF-36 revelou que na presente amostra, 
a qualidade de vida foi pior para o sexo 
feminino, e para pacientes de cor branca, com 
baixa escolaridade e sem parceiros estáveis. 
Conclusão: Os questionários aplicados 
permitiram identificar frequência e graus de 
ansiedade, depressão e comprometimento 
da qualidade de vida nos pacientes com 
doença renal familiar, que poderiam afetar a 
AbstRAct
Introduction: Psychological aspects 
and quality of life are often evaluated 
in patients under renal replacement 
therapy, but studies about anxiety, 
depression, and quality of life in 
familial renal diseases are lacking. 
Objectives: To evaluate the frequency of 
anxiety, depression, and quality of life 
(QOL) and their eventual associations 
with the main laboratory, clinical, 
socioeconomic, and cultural parameters 
in familial glomerulonephritis (GN) or 
autosomal dominant polycystic kidney 
disease (ADPKD). Methods: Ninety 
adult patients (52 familial GN and 38 
ADPKD) completed the questionaires of 
State Trait Anxiety Inventory (STAI), 
Beck Depression Inventory (BDI), and 
QOL-Short-Form SF-36, and were also 
submitted to a short interview. Results: 
Moderate anxiety was detected in both 
groups. Depression was found in 34.6% 
of familial GN and 60.5% of ADPKD 
patients. Anxiety and depression were 
more associated with female gender in 
familial GN, and with poorer schooling 
in ADPKD. Patients of both groups 
presented two quality of life unfavorable 
dimensions: emotional role function and 
general health perception. In addition, 
quality of life was worse among females, 
unmarried, and Caucasian subjects, 
and those individuals with a poorer 
educational level. Conclusion: The 
use of these instruments allows one to 
appreciate the frequency and levels of 
anxiety, depression, and quality of life 
in patients with familial renal diseases 
that could affect their compliance to 
treatment. These findings can contribute 
to planning a better multidisciplinary 
assistance to such groups of patients.
Anxiety, depression, and quality of life in patients with 
familial glomerulonephritis or autosomal dominant 
polycystic kidney disease
Ansiedade, depressão e qualidade de vida em pacientes com 
glomerulonefrite familiar ou doença renal policística autossômica 
dominante
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IntRoductIon
Information regarding the presence of genetic disease 
causes individuals, who once believed to be healthy, 
to become aware of their genetic potential to develop 
some type of disease in the future or to transmit it to 
their descendants. Examples of such diseases include: 
familial glomerulonephritis (GN) and autosomal 
dominant polycystic kidney disease (ADPKD), besides 
other familial chronic renal diseases.
It is important to point out that Online Mendelian 
Inheritance in Man (OMIM) has already registered 
more than 50 renal diseases with genetic origins and 
that the presence of family history of end-stage chronic 
kidney disease (CKD) is a significant risk factor for 
the subsequent development of nephropathy.1,2
ADPKD is one of the most common genetic 
diseases in the USA, with the prevalence of 1/800 
individuals.3 Also, it is the underlying cause of end-
stage renal disease in up to 10% of the cases. It has 
already been proved that ADPKD and depression 
are positively associated, in a statistically significant 
manner, in patients who initiated home hemodialysis.4 
The concomitant depressive symptoms, or even 
depression, in patients undergoing dialysis are 
also frequently reported, and such conditions may 
represent another risk factor for mortality, apart from 
predicting morbidity.5-9 Indeed, most studies have 
evaluated depression and quality of life in patients 
with kidney disease, who were submitted to dialysis 
or kidney transplant. Few studies have evaluated 
these aspects during the early stages of CKD, when 
renal function begins to decline.
Nowadays, it is worth to mention that depression is a 
significant disease, and the World Health Organization 
(WHO) estimates that in the beginning of the 21st 
century, it will be the second most common debilitating 
disease in the world.10 Projections for 2020 place it as 
a relevant cause for the decrease in life expectancy 
in developing countries, being responsible for 5.6% 
of the cases. In fact, some depressive symptoms may 
be in the lack of compliance: discouragement, loss of 
motivation and energy, difficulty in concentrating and 
memorizing, and social isolation, compromising the 
adherence to therapeutics and modulating nutritional 
and immunological situations.12,13
The first studies on the psychological aspects in 
familial renal diseases were performed by Manjoney 
and Mckegney, in 1978. They studied families 
with ADPKD, and the most important finding 
corresponded to “feeling guilty” for the transmission 
of a genetic disease to the family members.14 Torra 
and Ballarin added that having a guilty conscience 
and not speaking about the disease were the aspects 
observed in members of families with hereditary renal 
diseases.
On the other hand, “denial” is a universal initial 
answer to a traumatic experience, and, without 
any doubt, it was the most common psychological 
defense observed in patients with Alport syndrome. 
One of the patterns that repeated itself was 
the combination of mother’s depression and an 
overprotective attitude towards a son who is affected 
by the Alport syndrome. From that, it became clear 
that families with any kind of manifestation of 
Alport syndrome should be encouraged to openly 
discuss previous history of family members, their 
fears, feelings or guilt, their expectations and hopes. 
The role of the doctor and an empathetic attitude 
are essential for this process. Mothers with little 
or no manifestation of the disease, whose children 
have Alport syndrome, seem to have a special need 
for psychological support.15
As to the quality of life, some studies have shown 
that anemia, age, ethnicity, general clinical condition, 
type of dialysis, sedentarism, sleep disturbance, 
pain, erectile dysfunction, affective depression, 
and dissatisfaction with medical assistance may be 
associated with a different perception of quality of life 
in patients with end-stage renal disease.16
The aim of the present study was to describe 
anxiety, depression, and quality of life in patients 
with familial renal diseases, as well as to evaluate 
the clinical, laboratory, social, cultural, and 
economic markers that are eventually associated 
with such conditions in patients with familial GN 
and ADPKD.
Keywords: anxiety, depression, quality of life, 
glomerulonephritis, chronic kidney failure.
aderência desses pacientes ao tratamento. Esses achados 
podem contribuir para o planejamento de um melhor 
atendimento multidisciplinar para ambas as doenças.
Palavras-chave: ansiedade, depressão, qualidade de 
vida, glomerulonefrite, falência renal crônica.
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mAteRIAls And methods
The present study was performed in 52 outpatients with 
familial GN, - and 38 outpatients with ADPKD, that 
were assisted respectively at the Glomerulonephritis 
Ambulatory Care Unit at the Polycystic Kidney Disease 
Unit of the Nephrology Division from Universidade 
Federal de São Paulo (São Paulo, Brazil).
The criteria for selection were: patients who had 
familial GN (the focus was family involvement) 
or ADPKD; patients aged at least 18 years, and 
assisted in the aforementioned clinics. ADPKD 
diagnosis was based on family history of the illness, 
that is, an ancestor (father or mother) affected, and 
renal ultrasonography showing cysts, fulfilling the 
criteria proposed by Pei et al.17 for each age group. 
The criteria for exclusion were: patients presenting 
oligophrenia or those who were illiterate. The study 
was approved by the Local Ethics Committee from 
the University. After signing the consent form and 
agreeing to participate in the study, the patients filled 
out the State Trait Anxiety Inventory (STAI), Beck 
Depression Inventory (Beck), and SF-36 (Medical 
Outcomes Study 36-Item Short-Form Healthy 
Survey). The instruments were used according to 
their standardization, that is, respecting time limits, 
verbal instructions, preliminary demonstrations, and 
the ways to answer the questions, in the following 
sequence: STAI, Beck, and SF-36.
As to the instruments used in the study, the STAI 
self evaluation survey comprises two scales to analyze 
the anxiety state (STAI – state) and the anxiety trait 
(STAI – trait). Each involves 20 statements (with a 
scale of 1 to 4). Therefore, the total score of each 
scale may vary from 20 to 80, and the highest values 
indicate high levels of anxiety. These scores represent 
low (20-30), average (31-49), and high (≥50) levels 
of anxiety. Regarding the anxiety scales, STAI is one 
of the scales most commonly used around the world. 
STAI was validated in Brazil18-21 and was approved 
for scientific research, according to resolution nº 
002/2003 of Federal Council of Psychology - although 
it also recommends reviewing and updating normative 
data. The fact that it has been used in several theses 
in Brazil,22-24 as well as in scientific articles,20,21,25 also 
reinforces its applicability.20-22,24,25 Authors consider 
that, in order to standardize the language between 
studies of different origins, the use of such instrument 
aggregates information and, therefore, it was adopted 
in the present study.
Beck Depression Inventory is a self-applicable 
evaluation compounded of 21 items, each with 
four options, with scores varying from 0 to 3, in 
which 3 is the worst condition. The items refer to 
sadness, pessimistic thinking, feeling of failure, self 
dissatisfaction, guilt, punishment, self-loathing, self-
accusations, suicidal thoughts, crying, irritability, 
social withdrawal, indecision, change in self-image, 
difficulty to work, insomnia, fatigability, loss of 
appetite, weight loss, somatic concerns, and loss of 
libido. The total score is the sum of each item’s score 
(maximum of 63 points) and allows the classification 
of depression intensity levels (10-18 points: mild; 19-
29: moderate; ≥30: severe).
SF-36 is comprised of 36 questions that evaluate 
the following eight dimensions: physical functioning, 
physical role function, body pain, general health 
perception, vitality, social function, emotional role 
function and mental health. The values of each item 
vary from 0 to 100, in which 0 is the worst health 
situation and 100 is the best. SF-36 is one of the 
most common ways to evaluate the quality of life 
around the world, including of populations with 
CKD. It is classified as a generic instrument; one of 
its advantages is the possibility to evaluate several 
domains simultaneously, and the fact that it can be 
used in any population, besides allowing comparisons 
between patients with different diseases. Its only 
disadvantage is the impossibility to demonstrate 
alterations as to physical aspects.
A short interview with the patients was performed 
in order to document the knowledge in relation to 
the disease. Medical records of these patients were 
also used for data collection, aiming at presenting an 
overview of the clinical history.
The groups of patients were compared, taking 
into account clinical, laboratory, and demographic 
aspects, quality of life, anxiety, and depression scores, 
with ANOVA or Student’s t test. For the intragroup 
correlation, Spearman coefficient was used. A linear 
regression model was also built. P-values <0.05 were 
considered significant. The data were analyzed with 
SPSS for Windows, version 9.0.
Results
Fifty-two patients with familial GN and 38 with 
ADPKD participated in this study. They all had at 
least one first-degree relative with CKD.
Among the patients with familial GN, 27 had a 
previous renal biopsy, which determined the following 
diagnoses: 25.9%, focal segmental glomerulosclerosis; 
14.8%,  minimal change disease; 11.1%, membranous 
nephropathy; 11.1%, membranoproliferative 
glomerulonephritis; 7.4%, proliferative GN; 7.4%, 
IgA nephropathy; 3.7%, Alport syndrome; 3.7%, 
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C1q nephropathy; 3.7%, lupus nephritis; and 
11.1%, chronic GN with no conclusive histological 
diagnosis. The others had glomerular hematuria and/ 
or proteinuria without biopsy.
Patients or relatives with CKD secondary to diabetes 
and/or hypertension, nephrolithiasis and urinary 
infection were not included in the present study.
When demographic data, clinical and laboratory 
evaluations, and comorbidities of patients with 
familial GN were compared to those of individuals 
with ADPKD, there were no statistically significant 
differences, except as to the parameter “time of 
diagnosis”, which was longer in the group with 
ADPKD (p = 0.012) (Table 1). Hypertension and 
dyslipidemia were the most significant comorbidities 
found in both groups. Patients with familial GN 
presented diabetes mellitus secondary to the treatment 
with corticosteroids in 7.7% of the cases. As expected, 
end-stage renal disease was more frequently diagnosed 
in the ADPKD group than in the familial GN group 
(13.2% and 5.8%, respectively).
Mild level of state anxiety and moderate level of 
trait anxiety were observed in both groups. Anxiety 
was higher in women in the familial GN group. 
Besides, low schooling was associated with higher 
scores of trait anxiety in the ADPKD group (Table 2). 
Table 1 DemOgraphic, clinical, anD labOratOry Data Of familial gn anD aDpKD grOups. Data are 
presenteD as percentage, except when being expresseD Otherwise
Demographic, clinical, and laboratory data
Groups
 p-valueFamilial GN 
(n = 52)
ADPKD 
(n = 38)
Gender 0,097##
Female 31 (59.6%) 29 (76.3%)
Male 21 (40.4%) 9 (23.7%)
Age – years (average ± SD) 40.2 ± 12.6 38.5 ± 12.1 0.518#
Race/ skin color 0,054##
White (Caucasian) 40 (76.9%) 22 (57.9%)
Non-Caucasian 12 (23.1%) 16 (42.1%)
Time devoted to education 0.333**
(a) ≤ 8 years 30 (57.7%) 17 (44.7%)
(b) ≥ 8 and ≤ 11 years 17 (32.7%) 14 (36.8%)
(c) ≥ 11 years 5 (9.6%) 7 (18.4%)
Marital status 0.143##
Not married (single, separated, or divorced) 18 (34.6%) 19 (50.0%)
Married (or living together) 34 (65.4%) 19 (50.0%)
Religion 0.389**
Catholic 31 (62.0%) 16 (44.4%)
Protestant 10 (20.0%) 11 (30.6%)
“Those who believe in God, but don’t follow a religion” 7 (14.0%) 6 (16.7%)
Others† 2 (4.0%) 3 (8.4%)
Time of diagnosis mean (min.-max.) 4.5 (1 – 21) 6.0 (1 – 37) 0.012*
Serum creatinine at interview 
(mg/dl) mean (min- max.)
1.0 (0.6 – 2.0) 1.1 (0.7 – 1.9) 0.174*
Comorbidities
Hypertension 38 (73.1%) 24 (63.2%) 0.315##
Diabetes mellitus 4 (7.7%) - 0.135**
Hyperlipidemias 24 (46.2%) 11 (29.0%) 0.098##
End-stage renal disease∞ 3 (5.8%) 5 (13.2%) 0.275**
# Student’s t Test; ## χ2; * Mann-Whitney Test; ** Fisher Test; † Atheism, Kardecism and Buddhism; ∞ End-stage renal disease: 
chronic kidney disease in need of renal replacement therapy.
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When the state anxiety inventory was given to both 
groups, the most frequently observed answers were 
feelings of anxiety, “not feeling at home”, concerns 
about adversities and lack of happiness.
In the trait anxiety inventory, tension, concerns 
related to constantly thinking about problems, 
tiredness, and persistent ideas without a real 
importance, which keep the person busy, were the 
most frequent answers for both groups.
Depression was detected in 34.6% of the patients 
with familial GN and in 60.5% of the patients with 
ADPKD. Among the patients with familial GN and 
depression, only 9.6% were under antidepressants, 
but they were not regularly assisted by a professional 
specialized in mental health. None of the patients 
with ADPKD were using antidepressant medication 
nor undergoing therapy for treating depression.
In relation to the Beck inventory data, a statistically 
significant interaction between gender and time of 
diagnosis was observed (linear regression model, p = 
0.019). The most common answers to the questions 
in the Beck depression inventory were: loss of libido, 
concerns about physical health, sleep disturbance, 
fatigue, and difficulty to work.
The worst dimensions of quality of life evaluated 
by the SF-36 in both groups corresponded to general 
health situation and emotional aspects. On the other 
hand, the best dimension was physical capacity.
A linear regression model was adjusted, taking 
demographic variables, clinical and laboratory 
evaluations into account, as well as the results of 
the anxiety, depression, and quality of life surveys. 
Results with p < 0.05 are presented in Tables 3 and 4 
for the familial GN and ADPKD groups, respectively. 
No correlation was observed between the laboratory 
markers (proteinuria and serum creatinine) and 
anxiety, depression, and quality of life.
As for the familial GN group, whenever there 
was a one year increase in age,  a reduction of 1.18 
points was expected in the “physical” domain (p = 
0.007). Physical capacity of non-Caucasian patients 
was better than the Caucasian group (p = 0.026). 
Gender was associated with vitality (p = 0.025). On 
average, male patients presented 21.4 ± 8.1 more 
points in vitality than the female patients (p = 0.011). 
Regarding mental status, it was observed that male 
patients presented on average 21.6 ± 7.0 more points 
than the female patients (p = 0.003).
Table 2 levels Of anxiety, DepressiOn, anD quality Of life Of patients with familial gn anD aDpKD. 
Data are presenteD as means ± sD, except when being expresseD Otherwise
# Student’s t Test; ##  χ2;* Mann-Whitney Test; ** Generalization of Fisher Exact Test.
Evaluated Parameters
Groups
p-valueFamilial GN 
(n = 52)
ADPKD 
(n = 38)
STAI - state 39.5 ± 10.6 37.1 ± 10.8 0.296#
STAI - trait 47.9 ± 12.4 47.4 ± 12.6 0.849#
Beck mean (min. – max.) 7 (0 – 43) 11 (1 – 38) 0.011*
Beck (n of patients and %)   0.039**
No depression 34 (65.4%) 15 (39.5%)  
Mild to moderate 10 (19.2%) 17 (44.7%)  
Moderate to severe 6 (11.5%) 5 (13.2%)  
Severe 2 (3.8%) 1 (2.6%)  
SF-36    
Functional capacity 84.9 ± 17.5 83.7 ± 16.6 0.739#
Physical aspect 70.2 ± 39.9 71.1 ± 43.7 0.923#
Pain 75.8 ± 29.4 80.4 ± 31.5 0.479#
General health perception 54.7 ± 25.4 54.7 ± 23.3 0.999#
Vitality 64.6 ± 30.2 67.6 ± 29,0 0.633#
Social aspect 77.6 ± 30.4 68.4 ± 35,1 0.186#
Emotional aspect 56.4 ± 43.6 50.9 ± 45,7 0.561#
Mental health 68.8 ± 26.8 67.1 ± 25,4 0.749#
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Considering the ADPKD group, it was observed 
that whenever there was a one year increase in age, a 
reduction of 1.11 points in the body pain domain was 
expected  (p = 0.004). Married patients presented on 
average 18.0 ± 7+8 more points of mental health than 
the single patients (p = 0.028).
dIscussIon
In the anxiety and depression inventories, the patients 
had a higher score in the parameters related to 
fatigue, lack of energy, decreased sexual function, 
sleep disturbance, difficulty in keeping professional 
activities and making decisions. Similar aspects were 
also observed in a review published by Kimmel.26
The highest anxiety scores were found among 
women and single patients, which is also in accordance 
with the findings of Andrade.27 Women presented 
more depression and the worst scores in all quality of 
Table 3 levels Of anxiety, DepressiOn, anD 
quality Of life versus DemOgraphic 
Data in patients with familial gn 
(Only cOrrelatiOns Of p < 0.05)
# Student’s t Test; * Mann-Whitney Test.
Familial GN (n = 52) Mean ± SD p-value
STAI - state
Female 42.3 ± 10.0 p = 0.021#
Male 35.4 ± 10.3
STAI - trait
Female 51.4 ± 12.0 p = 0.011#
Male 42.7 ± 11.2
Beck mean (min. – max.)
Female 8 (1-30) p = 0.013*
Male 3 (0-43)
SF-36 
Functional capacity
Female 81.0 ± 18.8 p = 0.035#
Male 90.7 ± 13.6 p = 0.001#
White 82.1 ± 18.8
Non-White 94.2 ± 5.6
Vitality
Female 56.0 ± 31.1 p = 0.008#
Male 77.4 ± 24.4
Mental health
Female 60.1 ± 26.5 p = 0.003#
Male 81.7 ± 22.0
Table 4 levels Of anxiety, DepressiOn, anD 
quality Of life versus DemOgraphic 
Data in patients with aDpKD (Only 
cOrrelatiOns Of p < 0.05)
# Student’s t Test; * Mann-Whitney Test; † Kruskal Wallis Test; SD: 
standard deviation; ∞ Formal Education: time devoted to formal 
education – (a) ≤ 8 years; (b) ≥ 8 and ≤ 11 years; (c) ≥ 11 years.
ADPKD (n = 38)
Mean 
(min. –max.)
p-value
STAI - trait
Female 51 (23-73) p = 0.016*
Male 36 (27-55)
Formal Education∞
(a) 55 (34-71) p = 0.017†
(b) 48 (23-73)
(c) 36 (30-67)   
Beck
Female 13 (1-38) p = 0.038*
Male 8 (1-16)
Formal Education∞
(a) 15 (6-38) p = 0.010†
(b) 9.5 (1-16)
(c) 7 (1-16)
SF-36 
Functional capacity
Formal Education∞
(a) 75 (35-100) p = 0.001†
(b) 90 (85-100)
(c) 95 (80-100)  
Physical aspects
Formal Education∞
(a) 25 (0-100) p = 0.035†
(b) 100 (0-100)
(c) 100 (75-100)
Pain
Formal Education∞
(a) 72 (0-100) p = 0.017†
(b) 100 (41-100)
(c) 100 (100-100)  
Mental health  
Formal Education∞  
(a) 68 (1-100) p = 0.058†
(b) 80 (28-100)  
(c) 84 (44-92)  
Not married (mean ± 
SD) (single, separated, 
or divorced)
58.1 ± 26.6 p = 0.028#
Married (mean ± SD) 
(or living together)
76.0 ± 21.1
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life domains. Similarly, some authors had previously 
observed that women’s scores were worse than men’s, 
possibly due to the loss of social support.28
It is noteworthy that anxiety scores (trait and state) 
of patients with familial GN and ADPKD were worse 
than the ones of patients with diabetes and women 
with family history of breast cancer in the United 
Kingdom.29,30
The patients in this study reported sleep 
disturbances in the Beck inventory. It was observed 
that such disorders are often associated with a higher 
risk of cardiovascular disease, and a high percentage 
of patients in hemodialysis silently suffer from sleep 
disturbances. Therefore, such condition has been 
underdiagnosed.31 This profile certainly has several 
causes, including psychological problems, especially 
depression.32 The present findings are in accordance 
with previous studies, since anxiety and depression 
have already been related to the poor quality sleep in 
patients who underwent renal transplant.33
It is worth to mention that depression is a psychiatric 
disorder that affects the general population at an 
estimated frequency of 3% to 5%. When associated 
with other clinical conditions, it determines a poorer 
prognosis, lower adherence, increased morbidity and 
mortality rates. Depression is often underdiagnosed 
and not treated properly,8,11,34,35 even in patients with 
end-stage renal disease.36,37 In a study carried out in 
Turkey, 24% of the 50 patients with end-stage renal 
disease suffered from depression.38 Other  studies show 
that 30% of patients with such disease suffered from 
depression, reinforcing that advanced stage of CKD is 
associated with a bad quality of life.13,39 Besides, the 
risk of suicide is higher among these patients than in 
the general population.40
In the present study, depression was observed in 
34.6% of familial GN cases and in 60.5% of ADPKD 
cases. Female patients with ADPKD presented higher 
levels of anxiety than the ones in the familial GN 
group. Both groups had a greater proportion of 
depressed patients than the CKD, hemodialysis and 
continuous ambulatory peritoneal dialysis groups 
in the study in Turkey (33.8%, 19.2%, and 12.8%, 
respectively).41
Data related to a more appropriate therapeutic 
approach for depression are scarcer, but the 
importance of selective serotonin reuptake inhibitor 
has been reported, cognitive-behavioral therapy and 
working with a group that offers social support 
for the depression treatment in patients with CKD; 
pharmacotherapy is always recommended. Among 
the strategies to treat anxiety and depression, as well 
as to improve quality of life, some studies suggest 
regular physical exercises. Social support is also 
considered to be a relevant aspect of the evolution 
of patients with CKD undergoing renal replacement 
therapy.42 Both social and family support may 
cooperate to improve patients’ conditions, and 
such approach is correlated to a better quality 
of life, increased compliance, satisfaction with 
physicians and caretakers, as well as increased level 
of religiousness and spirituality.43,44 The observation 
that married patients with ADPKD presented better 
mental health compared to the single ones is also in 
accordance with such findings.
Anxiety and depression may have contributed to 
a higher morbidity rate, previously related among the 
recipients of renal transplants, which would not only 
imply a poor quality of life, but also a worse marital 
relationship, sexual functioning and sleep quality.45
Regarding the quality of life, it has also been 
described that anemia is associated with improvement 
in some of the aspects evaluated by SF-36, especially 
in the vitality domain of patients with stage 5 CKD.46 
In this study, the vitality of women with familial GN 
was inferior to men’s. A possible explanation is that 
the vitality reduction in patients with CKD may be a 
consequence of anemia. However, this condition was 
not detected among the main comorbidities observed 
in both groups. Besides, no parameter in the physical 
examination or in the laboratory evaluation was 
associated with vitality.
It is interesting to observe that the scores of general 
health and emotional aspects of the patients analyzed 
in this study were worse than what has been described 
for individuals in hemodialysis in Brazil,47 as well as 
for those with testicular cancer in Norway,48 which 
demonstrates the influence of the studied conditions 
for these parameters.
The worst scores of trait anxiety, depression 
inventory, functional capacity, pain, physical, and 
mental health aspects were seen in patients with 
ADPKD. In this group, a lower schooling level was 
also observed. It is possible that these results are 
associated with the lower economic level and the 
consequent difficulty in accessing programs of kidney 
disease prevention, as well as the higher prevalence of 
malnutrition and depression.49
In relation to the reports of patients, the complaints 
usually referred to the health system as a whole, to 
the limitations imposed by the chronic condition of 
the disease and to the traumatic personal experiences, 
which could certainly influence the scores of the 
instruments used in the study.
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Hence, anxiety, depression, and alterations in the 
quality of life should be evaluated in the full context 
of patients’ inclusion. Sometimes these conditions 
may be connected to having a familial disease, or they 
are completely independent from such aspect.
In conclusion, it was considered that the patients 
and their relatives need psychological support to deal 
with anxiety, anger, guilt, depression, and acceptance 
of the diagnosis in cases of ADPKD.
Undoubtedly, patients with ADPKD should be seen 
by a nephrologist and a multidisciplinary nephrology 
team. The evaluation of anxiety, depression, and 
quality of life should be part of routine appointments 
with adequate and subsequent referral to mental 
health professionals. Therefore, it is expected that a 
proper treatment for psychiatric conditions improve 
the patient’s well-being and evolution.45
To sum up, anxiety, depression, and the quality of 
life indicators of patients with familial renal disease 
are not usually evaluated in an adequate manner in the 
health sector, which does not allow a proper diagnosis 
of possible disorders. In the population studied by 
the authors of this article, depression, moderate trait 
anxiety and loss of quality of life, especially in relation 
to some of the evaluated aspects, were observed. 
These findings may affect the lack of adherence to 
the treatment, among other factors, which could 
indirectly contribute with the poor evolution of the 
renal disease. Ultimately, this situation is certainly 
harmful and may pose a vicious circle comprised of 
mental disorders and unsatisfying compliance.
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